Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma
Beatrice M. Razzo(Sidney Kimmel Cancer Center), Alfred L. Garfall(University of Pennsylvania), Sara Whittington(UPMC Hillman Cancer Center), Wei‐Ting Hwang(University of Pennsylvania), George Mellgard(Memorial Sloan Kettering Cancer Center), Rajshekhar Chakraborty(Columbia University Irving Medical Center), Zachary Wolfe(Lehigh Valley Hospital-Pocono), Ellen M. Waugh(Sidney Kimmel Cancer Center), Samantha Le(UPMC Hillman Cancer Center), Adam Waxman(Hospital of the University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Adam Binder(Beth Israel Deaconess Medical Center), Ashkan Bigdeli(UPMC Hillman Cancer Center), Dan T. Vogl(University of Pennsylvania), Samer Al Hadidi(University of Arkansas for Medical Sciences), Carolina Schinke(University of Arkansas for Medical Sciences), Sarah Girgis(UPMC Hillman Cancer Center), Shivani Kapur(UPMC Hillman Cancer Center), Hira Shaikh(University of Iowa Hospitals and Clinics), Jacquelyn J. Roth(UPMC Hillman Cancer Center), Adam Cohen(UPMC Hillman Cancer Center), David Lieberman(University of Pennsylvania), Francesca I Nugent(University of Iowa Hospitals and Clinics), Christopher Strouse(University of Iowa Hospitals and Clinics), Leonard Fiannaca(UPMC Hillman Cancer Center), Sandra P. Susanibar-Adaniya(Hospital of the University of Pennsylvania)
Cited by 6
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
|Nature Medicine|2021|519
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
|Nature Communications|2017|418
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308
New Targetable Oncogenes in Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2013|298